Dr Reddys Laboratories Ltd Tumbles -1.46% in Today's Trading Session
After a -1.46% decline, Dr Reddys Laboratories Ltd shares are now trading at 1299.80. The stock has a PE ratio of 26.4800, an ROE of 11.0737 and a debt to equity ratio of 0.2041.
Dr Reddys Laboratories Share Price Live
DRREDDY
Live Dr Reddys Laboratories Share Price Chart
Dr Reddys Laboratories Performance
Days Range
| Previous Close | ₹1,319.00 |
|---|---|
| Open | ₹1,318.8 |
| Volume | 54,24,347 |
| Day's Range | ₹1,297.50 - ₹1,328.60 |
|---|---|
| 52W Range | ₹1,148.40 - ₹1,379.70 |
| Market Cap | ₹1,08,751.63 Cr |
Dr Reddys Laboratories F & O
Dr Reddys Laboratories Fundamentals
| ROCE(TTM) | 12.54 |
|---|---|
| P/E Ratio (TTM) | 26.16 |
| P/B Ratio | 2.87 |
| Industry P/E | 33.73 |
| Debt to Equity | 0.2 |
| ROE | 11.07 |
| EPS (TTM) | 50.27 |
| Dividend Yield | 0.61 |
| Book Value | 453.98 |
| Face Value | 1 |
| ROCE(TTM) | 12.54 |
|---|---|
| P/E Ratio (TTM) | 26.16 |
| P/B Ratio | 2.87 |
| Industry P/E | 33.73 |
| Debt to Equity | 0.2 |
| ROE | 11.07 |
|---|---|
| EPS (TTM) | 50.27 |
| Dividend Yield | 0.61 |
| Book Value | 453.98 |
| Face Value | 1 |
Dr Reddys Laboratories Financials
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|
| Net Sales | 8,545.20 | 8,804.90 | 8,727.00 | 7,516.20 |
| Expenses | 6,874.60 | 7,323.00 | 7,386.90 | 7,721.00 |
| Profit before tax | 1,905.00 | 1,744.80 | 1,543.20 | 199.70 |
| Operating Profit | 1,409.90 | 1,336.80 | 1,189.60 | 221.30 |
| Net Profit | 1,409.90 | 1,336.80 | 1,189.60 | 221.30 |
| EPS in Rs | 17.04 | 16.18 | 14.53 | 2.65 |
Dr Reddys Laboratories Shareholding Pattern
| Held by | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoters | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% |
| Flls | 37.29% | 36.36% | 35.52% | 33.2% | 33.08% |
| Dlls | 25.62% | 26.74% | 27.98% | 30.44% | 30.72% |
| Public | 10.45% | 10.27% | 9.86% | 9.72% | 9.57% |
About Dr Reddys Laboratories
History
Dr Reddy's Laboratories was incorporated in 1984 in Hyderabad. It was established by Dr Anji Reddy with an initial capital outlay of ₹25 lakh. Mr. Reddy was one of the pioneers of the active pharmaceutical ingredients or APIs industry in India. Before establishing Dr. Reddy’s Laboratories, he had already co-founded two bulk drug manufacturing ventures. The company made its beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (APIs) and commenced operations with a single drug in a 60-tonne facility near Hyderabad. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Thereafter, they entered the international market with exports of Methyldopa. In the year 1987, the company obtained the first USFDA approval for Ibuprofen API. In 1991, the company began production of Omeprazole, which is one of its most popular drugs. In 1993, the Dr. Reddy’s Research Foundation was established, which focused on drug discovery, especially for cancer and diabetes. In 1998, they started their biologics business to offer affordable medicine to the Indian consumer. In 2003, the company launched its first generic product, i.e. Ibuprofen, under their label in the US. In 2019, the company entered the nutrition segment in India through the launch of Celevida.Business Segments
Dr. Reddy's offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company focuses on areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's is today a global company with a strong presence abroad. Its major markets include - the USA, India, Russia, and Europe. The company has primarily 3 businesses:- Pharmaceutical services and active ingredients production - This is the largest source of revenue for the company, bringing in roughly 83% of the revenue in FY 2022. As of September 2023, the company offers 400+ generic drugs at affordable costs by leveraging its integrated operations. Drugs related to the nervous system bring in the most revenue.
- Global generic drug production - Dr. Reddy’s Laboratories works on API development to help its own generic drugs business become cheaper as well as to launch products in the market faster than its competitors.
- Proprietary Products - This mostly involves the company developing various formulas to enhance efficiency and ease of use, among other factors.
Key Personnel
Erez Israeli, CEO Erez Israeli is the Chief Executive Officer of Dr. Reddy’s Laboratories. He joined the company in April 2018 as Chief Operating Officer before becoming CEO in July 2019. Mr. Israeli has an MBA from Bar-Ilan University, Israel, as well as over 30 years of experience. He had earlier worked at Enzymotec, where he was the President and CEO. Before that, he worked at Teva Pharmaceuticals for 23 years. He has held a multitude of positions, especially in the field of sales and marketing. G V Prasad, Co-chairman and MD Mr. Prasad joined the company in 1990. He oversaw Dr. Reddy’s growth from a mid-sized domestic operation to a major global pharma brand today, with a presence in 66 countries and a valuation of billions of dollars. His focus is on research, innovation, transparency, business ethics and leaner corporate structures. He also focuses on mentoring leaders driving innovation in science, technology and digitalisation.Corporate Actions
Bonus Shares Dr Reddy’s Laboratories had announced a bonus share in 2006 in the ratio of 1:1. Stock Splits Dr Reddy’s Laboratories had last split its shares from a face value of ₹10 to ₹5 in 2001. Dr Reddys Laboratories has not announced any rights issues or buyback of shares so far. Mergers and Acquisitions- In 2022-23, Dr. Reddy's Holdings Limited got merged with Dr Reddy's Laboratories Ltd. The merger became effective in April 2022.
- DRS LLC in Russia merged into Dr. Reddy's Laboratories LLC in July 2022.
- In 2017, Dr. Reddy's Laboratories completed the acquisition of a 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC), based out of Kolkata, for a consideration of ₹2.05 crore.
- In 2016, Dr. Reddy’s Laboratories acquired 6 OTC brands from Ducere Pharma to enter the consumer health field.
- In 2002, the company had made its first overseas acquisition in the form of BMS Laboratories Ltd. and Meridian Healthcare in the UK.
Financial Highlights
- The company’s sales revenue has gone up by more than 100% in the period between March 2013 and March 2023.
- On the other hand, the company’s net profits have increased by nearly 200% in the same period.
- The company’s net cash flows have been volatile over the past years. From being in negative for the last few years, it increased to ₹1,286 crore in FY 2021, dropped to ₹3 in FY 2022 and further declined to -₹907 in FY 2023.
Parent Organisation
Dr. Reddy's
Managing Director
G V Prasad
Founded
1984
NSE Symbol
DRREDDY
Top Mutual Funds Invested in Dr Reddys Laboratories Share
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 1,799.2 -45.10 (-2.45%) | ₹4,32,096.23 | 1,548.0 - 1,916.6 |
| Divis Laboratories Ltd | 6,667.0 -130.50 (-1.92%) | ₹1,76,807.38 | 5,636.5 - 7,071.5 |
| Torrent Pharmaceuticals Ltd | 4,410.8 -127.00 (-2.80%) | ₹1,48,718.00 | 3,102.0 - 4,712.9 |
| Cipla Ltd | 1,401.0 -17.20 (-1.21%) | ₹1,12,970.91 | 1,165.7 - 1,673.0 |
| Zydus Lifesciences Ltd | 1,077.7 -8.10 (-0.75%) | ₹1,08,441.84 | 835.5 - 1,115.5 |
| Lupin Ltd | 2,267.7 -8.70 (-0.38%) | ₹1,03,900.02 | 1,836.8 - 2,494.0 |
Popular Stocks
Dr Reddys Laboratories Latest News
Dr Reddys Laboratories Ltd Share Price in Red Today, Down -0.46%
Dr Reddys Laboratories Ltd shares experienced a -0.46% reduction, with the current market price at 1312.90. Investors are carefully considering their positions and seeking insights into the stock's future performance.
Dr Reddys Laboratories Ltd Stock Nosedives Today
Dr Reddys Laboratories Ltd stock price decreased by -0.46%, with the current market value at 1312.90 per share. Investors are assessing the stock's potential for recovery and future growth prospects.
Dr Reddys Laboratories Ltd FAQs
What is the share price of Dr Reddys Laboratories Ltd (DRREDDY) shares?
Dr Reddys Laboratories Ltd (DRREDDY) share price as of May 29, 2026, on NSE is Rs 1303.5 (NSE) and Rs 1303.5 (BSE) on BSE.
Can I buy Dr Reddys Laboratories Ltd (DRREDDY) from Angel One?
Yes, You can buy Dr Reddys Laboratories Ltd (DRREDDY) shares by opening a Demat account with Angel One.
How do I buy Dr Reddys Laboratories Ltd (DRREDDY) from Angel One?
Dr Reddys Laboratories Ltd (DRREDDY) share can be bought through the following modes:
1. Direct investment: You can buy Dr Reddys Laboratories Ltd (DRREDDY) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Dr Reddys Laboratories Ltd (DRREDDY) shares.
1. Direct investment: You can buy Dr Reddys Laboratories Ltd (DRREDDY) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Dr Reddys Laboratories Ltd (DRREDDY) shares.
What is the main business of Dr Reddy?
Dr. Reddy's produces and sells a variety of medications both domestically and abroad. The business produces about 190 drugs, 60 active pharmaceutical ingredients (APIs) used in the production of pharmaceuticals, diagnostic tools, critical care products, and biotechnology items.
Who are the promoters of Dr Reddy?
The promoters are Dr. Reddy'S Holdings Limited, APS Trust, Samrajyam Reddy Kallam, Satish Reddy Kallam, Gunupati Venkateswara Prasad (Huf), G.V.Prasad, K.Satish Reddy (HUF), Anuradha Gunupati, G Anuradha, K. Deepti Reddy, G.V. Sanjana Reddy, G. Mallika Reddy, Sharathchandra Reddy Gunupati, K Shravya Reddy, K Vishal Reddy, VSD Holdings & Advisory LLP.
Who is the CEO of Dr Reddy?
Erez Israeli is the CEO of Dr. Reddy.
What is the market cap of Dr Reddys Laboratories?
The market cap of Dr Reddys Laboratories is Rs. 108751.63 Cr. as of 30/05/2026.
What is the current P/E ratio of Dr Reddys Laboratories?
The P/E ratios of Dr Reddys Laboratories is 26.16 as of 30/05/2026.
What is the current PB ratio of Dr Reddys Laboratories?
The PB ratios of Dr Reddys Laboratories is 2.87 as of 30/05/2026.
